KRAS and lung adenocarcinoma: In in vivo xenograft models of neuroblastoma[78,79], HCC (in which there was a JAK1 S703I mutation)[40], and KRAS-mutated lung adenocarcinoma[80], among others, ruxolitinib treatment significantly inhibited tumor growth.